US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
Micafungin (trade name Mycamine) is an echinocandin antifungal drug used to treat and prevent invasive fungal infections including candidemia, abscesses and esophageal candidiasis. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008. In 2013, Japan was the largest consumption place, with a consumption market share nearly 35.40%. In 2017, North America is the largest consumption place with the consumption market share of 28.98%.
Market Analysis and Insights: Global Micafungin Sodium for Injection MarketThe research report studies the Micafungin Sodium for Injection market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market. The global Micafungin Sodium for Injection market size is projected to reach US$ 301.7 million by 2026, from US$ 349 million in 2020, at a CAGR of -2.4% during 2021-2026.
Global Micafungin Sodium for Injection Scope and SegmentThe global Micafungin Sodium for Injection market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Micafungin Sodium for Injection market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
by Type, the market is primarily split into
- 50 mg Single-use Vial
- 100 mg Single-use Vial
by Application, this report covers the following segments
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
- Respiratory Mycosis
- Gastrointestinal Mycosis
The Micafungin Sodium for Injection key players in this market include:
Table of Contents Chapter 1. Preface 1.1. Report Description 1.1.1. Objective 1.1.2. Target Audience 1.1.3. Unique Selling Proposition (USP) & Offerings 1.2. Research Scope 1.3. Research Methodology 1.3.1. Market Research Process 1.3.2. Market Research Methodology 1.3.3. Level 1: Primary Research 1.3.4. Level 2: Secondary Research 1.3.5. Level 3: Data Validation and Expert Panel Assessment Report Description and Scope Chapter 2. Executive Summary 2.1. Global Micafungin Sodium for Injection 2019-2029 (USD Billion) 2.2. Global Micafungin Sodium for Injection: Market Snapshot Chapter 3. Global Micafungin Sodium for Injection - Industry Analysis | read more...